Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6250111 | European Urology Focus | 2015 | 13 Pages |
Abstract
We reviewed all the data on treatment with high-intensity focussed ultrasound (HIFU) for localised prostate cancer (PCa). The quality of the evidence is very low because the information is based on a series of patients who received HIFU treatment with no comparison with active surveillance or radical treatment. Case series suggest an overall survival rate up to 89% and a PCa survival rate up to 99% after 5 yr, but these numbers vary according to the patient's risk category. Longer term and effects on quality of life are unknown.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Geneviéve Veereman, Pascale Jonckheer, Anja Desomer, Hans Van Brabandt, Chris D'Hont, Roland Van Velthoven, Bertrand Tombal,